Slide 1: Genetic Technologies – Investor Update
Genetic Technologies – Investor Update The Future: Unlocking personalised preventative medicine August 9, 2023 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 2: Notice: Forward looking statements
Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require fu
Slide 3: Key Messages
Key Messages • Developed a clear Vision and Strategy to be leader in personalised predictive genomics • Our journey from R&D → Commercialisation and the pathway to profitability • Identified the Drivers of Revenue and Pathway to Profitability by the middle of FY25 • Strong momentum in commercial ope
Slide 4: World leader in personalised predictive genomics
VISION World leader in personalised predictive genomics Empowering individuals to take control of their health UNIQUE VALUE PROPOSITION Turning cutting-edge science into personalised, predictive tests driven by AI & machine learning techniques Backed by over 20 years of experience, our scientific an
Slide 5: World leading portfolio
World leading portfolio Most comprehensive guideline driven portfolio for human and animal health. • Patented GeneType Multi Risk Test • Non-Invasive Prenatal Testing (NIPT) • Carrier screen testing • Pharmacogenomics • Oncogenetic & Monogenic diseases • Pet care Revenues anchored by our 3 brands to
Slide 6: Global Overview
Global Overview 60 40 25 Employees Countries Patents Granted* (FTE) globally (9 Pending Worldwide*) 14 51 12 Test Tests Partner Categories Laboratories * Patents granted are specific to the GeneType portfolio of products * Patents granted are specific to the GeneType portfolio of 6
Slide 7: Collaborations
Collaborations Professor Graham Professor John Professor Jon Memorial Sloane Professor Bernard Ohio State Colditz Hopper Emery Kettering Cancer Rosner University Brigham & Women’s Deputy Director, Professorial Fellow at Professor of Primary Collaborating on a Collaborating on a Hospital and Harvard
Slide 8: Delivering Revenue and Growth
Delivering Revenue and Growth 29% Cash Receipts (A#039;000) Growth CASH RECEIPTS on LY $8,771 CASH BALANCE $6,789 FY23 A$8.8m A$7.9m* +29% half-year ending December 31, 2021 GROSS MARGIN GROSS MARGIN $89 A$4.2m 47% Full Year FY21 Full Year FY22 Full Year FY23 Strategic & Operational Highlights: • Group
Slide 9: Genetic Technologies ESG Focus Areas
Genetic Technologies ASX:GTG ESG Focus Areas ESG UPDATE Q4 2023 Highlights Q4: • Board And Executive teams clearly defined vision and purpose • Introduced updated Maternity Leave Policy exceeding mandatory level, addressing Pay Equity • Conducted Cybersecurity Training, addressing Risks and Opportun
Slide 10: Snapshot and Achievements last 12 months
Snapshot and Achievements last 12 months GeneType & Commercialisation EasyDNA & Affinity DNA Reimbursement activation ✓ FY23 Group Receipts A$8.8 million, up 29% ✓ Integrated 2 Acquisitions ✓ Independently developed Budget Impact Model (BIM) identifies US$1.4 billion dollars in ✓ GeneType risk test:
Slide 11: Pathways to Market
Pathways to Market Executing a multi-brand strategy Consumer initiated Direct to Consumer Medical & Payer Testing (DTC) testing (CIT) Business to Business (B2B) with medical supervision with no medical supervision Oncology – GTG [insert revenue structure Expanded Carrier testing & NIPT [insert reven
Slide 12: Our Innovation – Multi-Risk Test
Our Innovation – Multi-Risk Test GeneType can identify patients ’at risk’ before onset and aid in the early detection and treatment. GeneType Risk assessment test for breast cancer has demonstrated improved early stage detection by 18% and saving approx. US$1.4B per annum4 for the US payer GeneType
Slide 13: NEW Comprehensive Breast and Ovarian Cancer test
NEW Comprehensive Breast and Ovarian Cancer test Evaluates a woman’s risk of developing Breast and/or Ovarian Cancer in women 30 years+ 5% - Hereditary Cancer with known pathogenic variant BRCA1/2 10% - Familial cancer with no known pathogenic variant 85% - GeneType Patented integrated Breast and Ov
Slide 14: GeneType Identifies up to 9 Times More Cancer Risk Patients
GeneType Identifies up to 9 Times More Cancer Risk Patients Compared to Existing SoC Models1 The paper, titled “Integrating Personalised Medicine into Preventative Care through Risk Stratification” Published in the Journal of Precision Medicine 1 https://www.thejournalofprecisionmedicine.com/wp-cont
Slide 15: DTC - Growth strategy for EasyDNA
DTC - Growth strategy for EasyDNA PHASE 1 PHASE 2 Brand Re-Ignition Revenue and Growth Focus [insert revenue structure and [insert revenue structure and agreement types] Brand Refreshagreement types] Website Refresh Improved Lead Gen New Sales Channels Product list Product list Multi-brand Portfolio
Slide 16: Our Pathway to Profitability
Our Pathway to Profitability Our Journey from Extensive R&D to Revenue and Profitability Research, Development and Commercialisation and Pathway to Profitability Innovation Revenue Generation 2000 - 2024 - 2021 2022 2023 2021 2025 Pioneers in Genomics, Launched Patented Acquired Affinity DNA Global
Slide 17: Revenue Drivers and our Pathway to Profitability
Revenue Drivers and our Pathway to Profitability Q4 CY2024 Cash Flow positive* Q3 CY2024 12 months worth of self funding cash Q4 FY2024 - BD, License Agreement or Payer - Coding strategy and payment June’24 - NCCN guideline pathway to inclusion Q3 FY2024 Launch BD, License H1 FY2024 agreement or Pay
Slide 18: Summary
Summary • Developed a clear Vision and Strategy to be leader in personalised predictive genomics • Identified the Drivers of Revenue and pathway to profitability by the middle of FY25 • Strong momentum in commercial operations with +29% growth in customer receipts • We have a global operation, a com
Slide 19: Thank you
Thank you Investor Relations Adrian Mulcahy Market Eye – Automic Group www.linkedin.com/company/genetype-limited M: +61 438 630 422 E: adrian.mulcahy@automicgroup.com.au www.genetype.com 19
Slide 20: Appendices
Appendices 20
Slide 21: Board and Management: Sales and Scientific expertise leading GTG
Board and Management: Sales and Scientific expertise leading GTG Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Comm, FAICD, FCA, Chairman Non – Executive Director FGIA, FTIA, F Fin Non – Executive Director Non – Executive Director Dr. Jerzy “George” Erika Spaeth Simon Mo
Slide 22: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. A.Prof Ron Dick MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MD, MS, FACMG MBBS, FRACP, FCSANZ, Research & Education Lead, MWGO is Principal Fellow and Regional Medical Director
Slide 23: Financial Overview
Financial Overview • Net cash outflow of A$9.9 million for the 12 months to 30 June 2023. We continue to grow EasyDNA and Affinity DNA brand sales and develop and commercialise our geneType tests • Cash reserves will be directed: A$’000 30-June-23 30-June-22 Change • to support the commercialisation
Slide 24: Corporate Overview
Corporate Overview Top 50 share registry breakdown BNY Mellon Board & Management Other Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 4 August 2023 0.2c ADR price (USD) as at 4 August 2023 $0.79 Other, 24% Ord Shares on Issue (M) 11,542 ASX 52-week trading (AUD low/h
Slide 25: Our Intellectual Property
Our Intellectual Property 4 Patents granted in the US 9 Patent families pending • Patent No: US 11,257,569, Methods of • Breast cancer risk assessment assessing risk of developing a severe • Methods for assessing risk of developing prostate cancer response to Coronavirus infection • Methods for asse
Slide 26: Defined Terms
Defined Terms Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score - a number associated